Moderna Inc (MRNA) Share Price

RSV vaccine makers vying for market share in second year of shots

Analysts expect Moderna, which is rolling out its mRNA shot for the first time, to come in third this year as it works to build up recognition of its new shot. The company hopes the fact that it is the only shot available as a pre-filled syringe will help with its uptake.

"We are currently shipping mResvia to major retailers and other points of care and are well positioned in a competitive market," Moderna said in a statement.

Moderna is set to report its earnings on Thursday.

https://finance.yahoo.com/news/rsv-vaccine-makers-vying-market-100712623.html

When being injected

Causes other problems

Which is followed by

More injections

What a business plan

MRNA under $200

UK preparing 'public health response' after H5N1 virus jumps from mammals to humans in pandemic escalation

https://www.gbnews.com/health/bird-flu-pandemic-symptoms-2024-vaccine

Should Merck Buy Out Moderna on Keytruda–Cancer Vaccine Partnership?


https://www.biospace.com/deals/should-merck-buy-out-moderna-on-keytruda-cancer-vaccine-partnership

Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

https://brazilian.report/liveblog/politics-insider/2024/07/18/confirms-first-newcastle-disease-case-in-18-years/

https://edition.cnn.com/2024/07/19/health/bird-flu-colorado/index.html

Experimental mRNA Vaccine Hints at Potential Against Glioblastoma

https://www.cancer.gov/news-events/cancer-currents-blog/2024/glioblastoma-mrna-vaccine-layered-nanoparticle

$MRNA golden cross on MACD

Bird flu virus infection is usually diagnosed by collecting a swab from the upper respiratory tract (nose or throat) of the sick person.

How is bird flu being tested

To determine its existence

bird flu- https://fortune.com/2024/07/15/bird-flu-outbreak-colorado-farm-5-workers-test-positive-experts-warn-turning-point-urgent-action-health/

https://www.fool.com/investing/2024/07/14/is-moderna-stock-a-buy/

Melanoma cancer vaccine results “extremely impressive”
The first vaccine treatment for the form of skin cancer usually caused by sun damage could halve the risk of patients dying or the disease returning, according to early trial results.

Researchers led by a team at New York University combined a vaccine using the same mRNA technology as many COVID jabs with an established immunotherapy called pembrolizumab. It was given to patients after they had surgery to remove stage 3 or stage 4 melanoma.

After three years, 75% of those who had the vaccine and pembrolizumab were still cancer-free, compared to 56% of people who only received pembrolizumab.

Iain Foulkes, our executive director of research and innovation explained that the results “show positive signs of the mRNA vaccine’s long-lasting effectiveness”, although larger and longer trials are still needed.

Unlike traditional vaccines, which are used to prevent disease, cancer vaccines are used to treat cancers. The vaccine used in this trial, mRNA-4157 (created by Moderna), is different for every patient. Scientists personalise it to help people’s immune system identify their specific cancer cells. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, supports this by effectively taking the brakes off of immune cells called T cells.

Speaking to journalists at ASCO, Swanton called the results “extremely impressive”.

“The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. Ultimately it will contribute to survival rates improving continually over the next decades and more.”

https://www.sciencealert.com/new-bird-flu-discovery-suggests-cows-are-a-threat-for-future-pandemics

https://www.nature.com/articles/d41586-024-02237-4

https://www.reuters.com/business/healthcare-pharmaceuticals/bird-flu-strains-spread-around-globe-2024-07-10/

Santa Claus is there NO VAX

Through fear

And dominance

Without knowing

Its ramifications

If so

In what form

Shades of

Jussie Smollett

Do viruses exist

If he works for the government, why is he asking for donations?

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

https://www.labiotech.eu/in-depth/bridge-rna-gene-editing/

‘It’s Going to Be Catastrophic’: Why the Next Pandemic Will Be Worse Than COVID

https://www.dailysignal.com/2024/07/08/chinas-covid-deception-cost-us-18-trillion-1-1-million-lives/

$NOVAX

https://www.nature.com/articles/d41586-024-02170-6

long live the pussy NO VAX

It's the way it's been done

Since the old days

The Reach

Feel the pain

heal your brain.... useless NO VAX

Be afraid

But we can help

No worries

Bird flu spread to cows takes 'dangerous' step towards infecting humans through respiration, scientists warn

https://news.sky.com/story/bird-flu-spread-to-cows-takes-dangerous-step-towards-infecting-humans-through-respiration-scientists-warn-13175177

Japan to ban MRNA

As turbo cancers among vaxxed

Skyrocketing

Turbo cancers are exploding among the vaccinated according to Japan’s leading oncologist who has slammed the mainstream media and Big Pharma in the West for covering up the extent of the medical crisis engulfing the world.

Prof. Emeritus Dr. Masanori Fukushima was ordered by the Japanese government to investigate why excess deaths skyrocketed in Japan in recent years.

His findings were conclusive: mRNA has destroyed immune systems and opened a Pandora’s box of autoimmune diseases, neurodegenerative diseases, cancer, and infections.

The Professor has a dire warning for those in the West – do not listen to mainstream media and Big Pharma as they are not engaged in science, but rather a eugenics experiment, and they have proven themselves to be enemies of the people.

Mitsubishi Tanabe Pharma will co-promote MRNA’s vaccines_in Japan:

https://www.accesswire.com/viewarticle.aspx?id=886055&lang=en

Financial terms of the co-promotion have not been disclosed.

Don't see the free advertising like before

Will this affect the bottom line

What could happen

Moving forward

https://www.economist.com/the-economist-explains/2024/07/05/why-finland-and-others-are-vaccinating-people-against-bird-flu

$MRNA

Would depend on what's being hacked

Has nothing to do with health

What about clinicals

If this is major test

Sounds fishy

In a 153-page written ruling on Tuesday, Mr Justice Meade concluded one of the European Moderna patents, labelled EP565, was “invalid”.

But the judge said a different patent, called EP949, was “valid” and was infringed by Pfizer and BioNTech.

A Moderna statement said: “We are pleased that the UK High Court recognised the innovation of Moderna scientists by confirming the validity and infringement of the EP949 patent and that (the) defendants were not entitled to use Moderna’s patented technology for any infringing activity after March 7 2022.

https://www.standard.co.uk/news/crime/pfizer-moderna-high-court-netherlands-germany-b1168104.html

The article is behind a paywall—can you paraphrase the key points? TIA

Looking for the Best Health Hacks- Try Vaccines "anti-vax"

https://www.scientificamerican.com/article/vaccines-are-the-safest-health-hack/

Moderna secures partial victory in Covid vaccine legal fight

https://www.ft.com/content/c57bc08f-50b3-42ef-ad44-4d592b189ce7

Scientists wary of bird flu pandemic 'unfolding in slow motion'

"It almost seems like a pandemic unfolding in slow motion," said Scott Hensley, a professor of microbiology at the University of Pennsylvania. "Right now, the threat is pretty low ... but that could change in a heartbeat."

https://www.reuters.com/business/healthcare-pharmaceuticals/scientists-wary-bird-flu-pandemic-unfolding-slow-motion-2024-07-01/

10 clinical trials to watch in the second half of 2024
COMPANY: Moderna
DISEASE: Cytomegalovirus
TREATMENT TYPE: mRNA Vaccine

There are no vaccines for cytomegalovirus, or CMV.
Success would also open up the potential of a product analysts think could eventually generate more than $3 billion in peak yearly sales.

https://www.biopharmadive.com/news/biotech-10-clinical-trials-watch-2024-second-half/720005/

bouncer...

Making another buy call at this level

8+ billion cash

today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-Project-Award-through-BARDAs-Rapid-Response-Partnership-Vehicle-Consortium-to-Accelerate-Development-of-mRNA-based-Pandemic-Influenza-Vaccine/default.aspx

Combined COVID-flu vaccines are coming: Moderna jab clears major test

https://www.nature.com/articles/d41586-024-02121-1

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

https://investors.modernatx.com/news/news-details/2024/EMA-Committee-For-Medicinal-Products-For-Human-Use-Adopts-Positive-Opinion-Recommending-Marketing-Authorization-Of-Modernas-RSV-Vaccine-mRESVIAR/default.aspx

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Lin Guey, PhD, Chief Scientific Officer of Therapeutics Research Ventures and Biotherapeutics at Moderna, stated, "We are thrilled with the significant progress we've made in advancing in vivo CAR-M therapies alongside Carisma. We eagerly anticipate further development of the nominated candidate for patients with solid tumors, and we look forward to continued success as we develop additional in vivo CAR-M together to bring new therapies to patients with HCC and other cancers."

The in vivo CAR-M program targeting GPC3 is being developed under the 2022 strategic collaboration agreement between Carisma and Moderna to discover, develop, and commercialize in vivo engineered CAR-M therapeutics for the treatment of cancer. In addition to this program, Moderna has nominated four undisclosed oncology research targets under the collaboration. Carisma is responsible for the discovery and optimization of development candidates, while Moderna will lead the development and commercialization of resulting therapeutics.

https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-announces-nomination-first-vivo-car-m